Literature DB >> 28210785

On glioblastoma and the search for a cure: where do we stand?

John Bianco1, Chiara Bastiancich2, Aleksander Jankovski3,4, Anne des Rieux2,5, Véronique Préat6, Fabienne Danhier2.   

Abstract

Although brain tumours have been documented and recorded since the nineteenth century, 2016 marked 90 years since Percival Bailey and Harvey Cushing coined the term "glioblastoma multiforme". Since that time, although extensive developments in diagnosis and treatment have been made, relatively little improvement on prognosis has been achieved. The resilience of GBM thus makes treating this tumour one of the biggest challenges currently faced by neuro-oncology. Aggressive and robust development, coupled with difficulties of complete resection, drug delivery and therapeutic resistance to treatment are some of the main issues that this nemesis presents today. Current treatments are far from satisfactory with poor prognosis, and focus on palliative management rather than curative intervention. However, therapeutic research leading to developments in novel treatment stratagems show promise in combating this disease. Here we present a review on GBM, looking at the history and advances which have shaped neurosurgery over the last century that cumulate to the present day management of GBM, while also exploring future perspectives in treatment options that could lead to new treatments on the road to a cure.

Entities:  

Keywords:  Cancer stem cells; Drug delivery; Glioblastoma multiforme; Therapeutic resistance

Mesh:

Year:  2017        PMID: 28210785     DOI: 10.1007/s00018-017-2483-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  133 in total

1.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

2.  The crucial decade: modern neurosurgery's definitive development in Harvey Cushing's early research and practice, 1900 to 1910.

Authors:  S H Greenblatt
Journal:  J Neurosurg       Date:  1997-12       Impact factor: 5.115

3.  Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.

Authors:  Thibaut Fourniols; Luc D Randolph; Aurélie Staub; Kevin Vanvarenberg; Julian G Leprince; Véronique Préat; Anne des Rieux; Fabienne Danhier
Journal:  J Control Release       Date:  2015-05-15       Impact factor: 9.776

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

Review 5.  Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.

Authors:  C Bastiancich; P Danhier; V Préat; F Danhier
Journal:  J Control Release       Date:  2016-09-28       Impact factor: 9.776

6.  Grading of astrocytomas. A simple and reproducible method.

Authors:  C Daumas-Duport; B Scheithauer; J O'Fallon; P Kelly
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.

Authors:  Yulian P Ramirez; Ann C Mladek; Roger M Phillips; Mikko Gynther; Jarkko Rautio; Alonzo H Ross; Richard T Wheelhouse; Jann N Sakaria
Journal:  Mol Cancer Ther       Date:  2014-10-28       Impact factor: 6.261

9.  Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.

Authors:  Reena P Thomas; Lawrence Recht; Seema Nagpal
Journal:  Clin Pharmacol       Date:  2012-12-27

Review 10.  Galectins and gliomas.

Authors:  Marie Le Mercier; Shannon Fortin; Véronique Mathieu; Robert Kiss; Florence Lefranc
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

View more
  19 in total

1.  CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation.

Authors:  Aubin Moutal; Lex Salas Villa; Seul Ki Yeon; Kyle T Householder; Ki Duk Park; Rachael W Sirianni; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2017-06-28       Impact factor: 5.590

2.  PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.

Authors:  Stephen A Jannetti; Giuseppe Carlucci; Brandon Carney; Susanne Kossatz; Larissa Shenker; Lukas M Carter; Beatriz Salinas; Christian Brand; Ahmad Sadique; Patrick L Donabedian; Kristen M Cunanan; Mithat Gönen; Vladimir Ponomarev; Brian M Zeglis; Mark M Souweidane; Jason S Lewis; Wolfgang A Weber; John L Humm; Thomas Reiner
Journal:  J Nucl Med       Date:  2018-03-23       Impact factor: 10.057

3.  Tunneling nanotubes: A bridge for heterogeneity in glioblastoma and a new therapeutic target?

Authors:  Varun Subramaniam Venkatesh; Emil Lou
Journal:  Cancer Rep (Hoboken)       Date:  2019-05-08

4.  Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo.

Authors:  Francesca Vaglini; Carla Pardini; Teresa Di Desidero; Paola Orlandi; Francesco Pasqualetti; Alessandra Ottani; Simone Pacini; Daniela Giuliani; Salvatore Guarini; Guido Bocci
Journal:  Mol Neurobiol       Date:  2017-08-08       Impact factor: 5.590

5.  Glioma and microenvironment dual targeted nanocarrier for improved antiglioblastoma efficacy.

Authors:  Xiuzhen Wang; Qing Zhang; Lingyan Lv; Junjie Fu; Yan Jiang; Hongliang Xin; Qizheng Yao
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

6.  Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center.

Authors:  Amer Haj; Christian Doenitz; Karl-Michael Schebesch; Denise Ehrensberger; Peter Hau; Kurt Putnik; Markus J Riemenschneider; Christina Wendl; Michael Gerken; Tobias Pukrop; Alexander Brawanski; Martin A Proescholdt
Journal:  Brain Sci       Date:  2017-12-25

7.  STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma.

Authors:  Carla Lucia Esposito; Silvia Nuzzo; Silvia Catuogno; Simona Romano; Filomena de Nigris; Vittorio de Franciscis
Journal:  Mol Ther Nucleic Acids       Date:  2017-12-30       Impact factor: 8.886

Review 8.  The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor.

Authors:  Mariachiara Zuccarini; Patricia Giuliani; Sihana Ziberi; Marzia Carluccio; Patrizia Di Iorio; Francesco Caciagli; Renata Ciccarelli
Journal:  Genes (Basel)       Date:  2018-02-17       Impact factor: 4.096

9.  Novel Treatment for Glioblastoma Delivered by a Radiation Responsive and Radiopaque Hydrogel.

Authors:  Mathilde Bouché; Yuxi C Dong; Saad Sheikh; Kimberly Taing; Deeksha Saxena; Jessica C Hsu; Minna H Chen; Ryan D Salinas; Hongjun Song; Jason A Burdick; Jay Dorsey; David P Cormode
Journal:  ACS Biomater Sci Eng       Date:  2021-06-23

10.  Repression of Septin9 and Septin2 suppresses tumor growth of human glioblastoma cells.

Authors:  Dongchao Xu; Ajuan Liu; Xuan Wang; Yidan Chen; Yunyun Shen; Zhou Tan; Mengsheng Qiu
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.